CD33 and acute myeloid leukemia: A standard CD34+/CD117+/CD13+/CD33+ AML phenotype does not lend itself to the monitoring of MRD, since this is also the phenotype of normal bone marrow (BM) hematopoietic stem cells (HSCs).